Aby J. Mathew Sells 1,597 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 1,597 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $39,925.00. Following the sale, the executive vice president now directly owns 260,601 shares of the company’s stock, valued at $6,515,025. This represents a 0.61 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

BioLife Solutions Trading Down 4.6 %

Shares of BLFS stock traded down $1.21 during trading hours on Thursday, hitting $25.06. 278,326 shares of the company’s stock traded hands, compared to its average volume of 349,466. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The stock has a market cap of $1.18 billion, a PE ratio of -23.64 and a beta of 2.04. The stock’s 50 day simple moving average is $26.64 and its 200 day simple moving average is $25.51.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the business earned ($0.21) EPS. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Trading of BioLife Solutions

Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in shares of BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares during the period. Geode Capital Management LLC raised its position in shares of BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after acquiring an additional 18,473 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of BioLife Solutions by 40.8% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,463 shares of the medical equipment provider’s stock worth $487,000 after acquiring an additional 5,638 shares in the last quarter. Barclays PLC lifted its stake in shares of BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after purchasing an additional 10,803 shares during the period. Finally, D.A. Davidson & CO. bought a new stake in shares of BioLife Solutions during the 3rd quarter valued at about $1,018,000. 93.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. TD Cowen lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Craig Hallum upped their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright raised their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, Northland Securities upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.